The incidence and treatment of diabetic macular edema at the University Eye-Clinic Graz for a period of 2 years
| Autor: | Vanessa Gasser-Steiner, Monja Michelitsch, Peter Gasser-Steiner |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Endothelial Growth Factors
medicine.medical_specialty Visual acuity Triamcinolone acetonide genetic structures Bevacizumab business.industry Incidence (epidemiology) Diabetic macular edema Diabetic retinopathy medicine.disease eye diseases Ophthalmology Standard care Medicine medicine.symptom business medicine.drug |
| Zdroj: | Spektrum der Augenheilkunde. 27:234-238 |
| ISSN: | 1613-7523 0930-4282 |
| DOI: | 10.1007/s00717-013-0185-2 |
| Popis: | Background A leading cause for permanent vision loss in diabetic patients with diabetic retinopathy is the occurrence of diabetic macular edema. New treatments, antivascular endothelial growth factors, for diabetic macular edema (DME) have been under trial and found to improve visual acuity more effective than the standard care treatment, central photocoagulation. The purpose of the following study was to estimate the future number of visiting DME patients and their treatment demands at the University Eye-Clinic Graz. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink